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Abstract
Purpose—To study associations between serum and aqueous vascular endothelial growth factor
(VEGF) and insulin-like growth factor 1 (IGF-1) and macular edema measured with optical
coherence tomography (OCT) following phacoemulsification in diabetic patients.
Design—Cohort study
Methods—A pilot study of 36 consecutive diabetic patients undergoing planned
phacoemulsification with IOL in one eye by one surgeon at the University of North Carolina
consented to preoperative and postoperative OCT central subfield thickness measurements (CSF)
and aqueous and blood samples for VEGF and IGF-1. Four patients with CSME received laser
preoperatively. Spearman Rank correlations were performed between growth factors and mean CSF
or a clinically meaningful percent change in CSF (>11% of preoperative measurement) at one and 6
months postoperatively.
Results—There were no surgical complications or new cases of CSME following surgery. Mean
aqueous VEGF in patients with retinopathy, determined preoperatively, increased with increasing
level of severity. Patients with preoperative CSME also had severe or worse retinopathy and the
greatest mean aqueous VEGF. Significant preoperative correlations existed between aqueous VEGF
and more severe retinopathy, whether CSME was present or absent (r=0.49, P=.007), and between
aqueous VEGF and CSME (r=0.41, P=.029). At one month postoperative, aqueous VEGF was
positively correlated with >11% change from preoperative CSF, regardless of CSME status (r=0.47;
P=.027). No noteworthy associations existed between CSF and IGF-1 values.
© 2009 Elsevier Inc. All rights reserved.
Corresponding author: M. Elizabeth Hartnett, Dept of Ophthalmology, University of North Carolina, 5100 Bioinformatics Building, CB
#7040, USA, Phone: (919)-843-0298, hartnet@med.unc.edu.
C. Contribution of Authors: Design of Study (MEH); Conduct of the study (MEH, KLC); Collection, Management, Analysis and
interpretation of the data (MEH, LP, GK, PG, PR); Preparation, review or approval of the manuscript (MEH, LP, GK, PG, PR, KLC) D.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
B. MEH consults for Ophthalmic Research Associates. Dr. Koch is the principal investigator for cooperative agreements through the
University of North Carolina at Chapel Hill with over 20 pharmaceutical and biotechnology companies, with the most substantial of
these being with GlaxoSmithKline. None of these agreements have a specific relationship with the study reported in this paper. The
primary objectives for the cooperative agreements noted here pertain to matters of statistical methodology for the design, analysis, and
reporting of confirmatory clinical trials. Other authors have no financial disclosures.
D. This clinical study was approved by the University of North Carolina at Chapel Hill School of Medicine’s Committee on the Protection
of the Rights of Human Subjects and Institutional Review Board, and all research adhered to the tenets of the Declaration of Helsinki.
NIH Public Access
Author Manuscript
Am J Ophthalmol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:













Conclusions—Aqueous VEGF was significantly positively associated with a clinically
meaningful change in CSF in diabetic patients one month following cataract surgery. Accounting
for preoperative CSF was important. Further study is indicated.
INTRODUCTION
Cystoid macular edema (CME) and exacerbated diabetic macular edema can adversely affect
visual outcomes following cataract surgery in patients with diabetes mellitus1,2,3,4,5. With
technical improvements in cataract surgery, better glycemic control in patients with diabetes,
and preoperative laser treatment for clinically significant macular edema (CSME), long-lasting
macular edema following cataract surgery is reported less often now than in the past, but the
problem of postoperative macular edema still exists3,6. A 30% increase in the center point
thickness as measured by optical coherence tomography (OCT) was reported in 22% of patients
with diabetes at one month post-cataract extraction7. More than half had resolution at 3 months
in this study. However, delay in treatment of macular edema has been shown to reduce visual
improvement following cataract extraction in some patients8,9. Therefore, preoperative
measurements that identify patients at risk for macular edema after cataract surgery may be
beneficial to initiate treatment early and reduce vision loss from macular edema.
Vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) have been
implicated in the pathogenesis of macular edema and diabetic retinopathy. VEGF is a
vasopermeability factor10 and has been associated with diabetic macular edema11.
Intravitreous injections of agents that neutralize the bioactivity of VEGF have stabilized or
improved visual acuity and reduced central subfield thickness (CSF) as measured by OCT in
phakic patients with diabetic macular edema12 and have had mixed reports in non-diabetic
pseudophakic patients with cystoid macular edema13,14. Another study reported that elevated
aqueous levels of VEGF, IL-6, and protein were associated with exacerbated fluorescein
leakage in the maculas of diabetic patients 6 months following cataract surgery15. A recent
report showed that 8 patients with diabetes who had had intravitreous bevacizumab for CSME
prior to cataract surgery had reduced aqueous VEGF levels at the time of surgery two months
later, but only a transient reduction in CSF16. The efficacy of anti-VEGF treatment for
prevention or treatment of post-operative CME or exacerbation of CSME from cataract surgery
in patients with diabetes remains indeterminate and may require further study.
Increased serum IGF-1 has been positively associated with increased severity of diabetic
retinopathy17,18. High serum IGF-1 following intensive glycemic control was associated with
rapidly progressive diabetic retinopathy, and the severity of retinopathy was reduced with
ocreotide, a somatostatin analogue19. Transgenic mice that overexpress IGF-1 developed
retinal features similar to human diabetic retinopathy20. Furthermore, transgenic mice
expressing a growth hormone antagonist gene, or wild type mice treated with an inhibitor to
growth hormone, had reduced retinal neovascularization in an angiogenesis model21,22.
We performed a pilot study to determine the associations between the concentration of VEGF
or IGF-1 at the time of surgery and clinically meaningful macular thickening measured by OCT
at one month and 6 months following cataract surgery. Knowing relationships between
preoperative growth factor values and a change in the macular thickening may be useful to
determine if these factors increase the predictability of macular thickening and vision loss in
a diabetic patient anticipating cataract surgery. This information may then be useful in
designing future clinical studies to test the effect of treatments to prevent or treat macular edema
in diabetic patients undergoing cataract surgery.
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Consecutive patients with type II diabetes mellitus (DM) who consented to have aqueous and
blood samples obtained at the time of planned phacoemulsification and intraocular lens
placement, were enrolled between August 2005 and August 2006 from the practice of one
experienced cataract surgeon. Patients with known vein or artery occlusions, other
retinovascular disease, uveitis or previous vitrectomy or eye surgery were excluded. There
were 36 patients with diabetes, 20 female and 16 male. The average age was 67.5 years. Media
opacity from cataracts precluded preoperative grading of retinopathy severity in one patient
and accurate measurements by OCT in 7 patients because of low image saturation. All patients
had uncomplicated phacoemulsification with posterior chamber intraocular lens implantations.
Serum and aqueous samples from 3 patients were not received in the laboratory. An additional
4 patients had insufficient aqueous for analysis of some growth factors.
Preoperative assessments were performed within 2 weeks of surgery and included undilated
LogMAR best corrected visual acuity (VA) using the ETDRS chart, slit-lamp biomicroscopy,
indirect ophthalmoscopy, intraocular pressure measurement, and biometry to calculate IOL
power. OCT was performed at the preoperative visit by a trained masked ophthalmic
photographer using the Stratus OCT-3 (Carl Zeiss Meditec) and central subfield thickness
(CSF) was recorded and analyzed.
The severity of diabetic retinopathy was diagnosed at the preoperative visit using slit-lamp
funduscopic biomicroscopy and classified as no retinopathy, mild non-proliferative
retinopathy (NPDR), moderate NPDR, severe NPDR, or proliferative retinopathy (PDR) based
on the International Clinical Diabetic Retinopathy Disease Severity Scale23. A score (S) of 1
for no retinopathy (S1) to 5 for PDR (S5) was used in analyses. In binary analyses, patients
with none or mild NPDR were collapsed into one category and compared to those with
moderate NPDR or worse. CSME was defined by criteria in the Early Treatment Diabetic
Retinopathy Study (ETDRS) as retina thickening within 500 µm of the fovea, hard exudates
within 500 µm of the fovea in association with retinal thickening or retinal thickening one disc
area or larger within one disc diameter of the fovea. Patients with CSME were treated with
laser based on the ETDRS24 at least one month before cataract surgery and were deemed to
have had maximal treatment prior to cataract surgery. No patients had preoperative
intravitreous triamcinolone or bevacizumab injections.
Acquisition of serum and aqueous samples
At the time of surgery, 100–200 µL of aqueous humor was withdrawn from the anterior
chamber using a tuberculin syringe attached to a 30 gauge needle via a paracentesis prior to
instillation of viscoelastic. Blood samples were drawn into serum separation tubes (BD,
Franklin Lakes, NJ) and allowed to clot for 30 to 60 minutes at room temperature. The sterile
aqueous sample was placed on ice for transfer. Both samples were labeled with a unique
identification number and transferred to the laboratory where they were centrifuged at 14000
rpm for 10 minutes at 4°C. The supernatants were rapidly frozen and stored at −80°C until
analyses were performed.
Measurement of VEGF and IGF-1
VEGF and IGF-1 levels were measured in aqueous and serum samples by an experienced
masked lab technician using commercially available enzyme-linked immunosorbent assay
(ELISA) kits for human VEGF or IGF-1 (R&D Systems, Minneapolis, MN; mean minimum
detectable dose: VEGF [6.4 pg/mL, catalog number DVE00], IGF-1 [0.026 ng/mL, catalog
number DG100]) according to manufacturer’s instructions. IGF-1 serum samples were
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incubated with pretreatment reagents supplied with the kit prior to assay to release IGF-1 from
binding proteins. Sample values were expressed as pg/mL (VEGF) or ng/mL (IGF-1) based
on standard curves plotted using protein standards supplied with the kits. In cases in which
aqueous collection was less than 150 µL, a dilution with phosphate buffered saline of up to 1:4
was used. The effect of dilution was then corrected when determining final values.
Postoperative assessment
The main outcome measures were LogMAR visual acuity and CSF variables determined
postoperatively at 1 month and 6 months (mean CSF, and change in CSF >11% of preoperative
CSF measurement).
Statistical analysis
At the time of designing this pilot study, there were few data on associations between OCT
parameters and growth factor values in patients with diabetes. Also since the inception of the
study, the Diabetic Retinopathy Clinical Research Network published that preoperative values
of the CSF of the OCT are important when interpreting postoperative measurements.
Specifically, a clinically meaningful change in CSF was equivalent to 11% of preoperative
CSF25, rather than an absolute value, such as 25 µm, used in previous studies (> 2 S.D. of
baseline OCT26). This guideline has not yet been universally accepted; therefore, we
determined associations between mean growth factor values and mean CSF as well as the
percent change in postoperative CSF of at least 11% of the preoperative value.
Means and standard deviations are used to describe continuous variables and frequency
distributions are used to describe categorical variables.
Retinopathy was analyzed by the category of severity or as a binary variable comparing no and
mild NPDR to moderate NPDR or worse. Associations among preoperative mean CSF, change
in CSF >11% of preoperative value, LogMAR visual acuity, serum and aqueous growth factors,
and severity of retinopathy determined categorically or as a binary variable were assessed using
Spearman rank correlations.
For all analyses of this pilot study, a criterion of p≤0.05 was used as a guideline to identify
associations of potential interest for future study. All analyses were performed with SAS system
software (SAS Institute Inc., Cary, N.C.).
RESULTS
Preoperative variables of all patients, categorized as those with and without CSME and by level
of retinopathy severity, are shown in Table 1. When considering diabetic patients regardless
of CSME status, the average HbA1C was 6.7± 1.2 % (range: 5.2 – 9.8) with a median value
of 6.4%. Of diabetic patients without CSME, 19 had no retinopathy; 6 had mild NPDR; 5 had
moderate NPDR; and 1 had PDR. Of those 4 with CSME, 3 had severe NPDR and 1 had PDR.
(The media opacity from cataract precluded accurate classification of retinopathy in one
patient.) All patients with CSME had been treated with laser prior to cataract surgery based on
ETDRS recommendations24. Aqueous IGF-1 was below detection by ELISA in all patients
(binding proteins had been released with pretreatment reagents to maximize the measurement
of IGF-1). There was a progressive increase in mean aqueous VEGF levels from mild NPDR
to severe PDR and to CSME, which included eyes with severe NPDR and PDR (Table 1). The
increase in mean aqueous VEGF levels with increasing levels of retinopathy severity existed
when the CSME group was removed and these values were included in appropriate retinopathy
severity groups (data not shown).
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In analyzing preoperative variables for all diabetics regardless of CSME status, there was a
strong positive correlation between aqueous VEGF and more severe retinopathy when analyzed
by category of retinopathy severity (r=0.43; P=.020; Table 2) and a very strong positive
correlation with moderate NPDR or worse in a binary analysis (r=0.49; P =.007). The same
relationships were not found for serum VEGF or IGF-1. When analyses were performed on
diabetic patients without CSME, there was a trend toward increased mean aqueous VEGF and
moderate or worse retinopathy in a binary analysis (r=0.35; P =.085), but no significant
difference was found in a categorical analysis (Table 2). There was a positive correlation
between mean aqueous VEGF and the presence of CSME (r=0.41; P =.029) and a positive
trend between mean serum VEGF and CSME (r=0.30; P=.091).
Descriptive statistics for postoperative outcomes at one and 6 months are presented in Table
3 for all diabetic patients, divided into those with or without CSME, and categorized by level
of retinopathy severity. Of note, the one month postoperative increase in CSF >11% of the
preoperative measurement was found in 6 patients, 2 without CSME and in 4 with CSME.
Analyses of postoperative correlations of all patients with diabetes, regardless of CSME status,
are shown in Table 4. Of note, aqueous VEGF was positively correlated with change in CSF
> 11% of the preoperative measurement (r=0.47; P =.027) at one month after surgery. There
were also strong positive correlations between more severe retinopathy, analyzed categorically,
and mean CSF at one (r=0.64; P =.0003), 6 months (r=0.47; P =.017) and change in CSF >11%
of the preoperative measurement at one month (r=0.53; P =.009). Similar relationships were
present when retinopathy severity was analyzed in binary fashion. There was a trend toward
increased mean serum VEGF and percent change in CSF >11% from the preoperative value
at one month (r=0.37, P =.092).
Discussion
In this pilot study, we determined associations between VEGF or IGF-1 levels at the time of
surgery with macular thickening measured as central subfield thickness (CSF) by OCT at one
month following uncomplicated phacoemulsification. We found that aqueous VEGF correlated
positively with a clinically meaningful change in CSF (>11% of preoperative value),
suggesting it may have predictive value in determining diabetic patients at risk for macular
edema following cataract surgery. We included diabetic patients with and without CSME
because both CME and CSME can lead to vision loss following cataract surgery, and there are
common factors in the pathogenesis (for example, inflammatory cytokines). However, we also
divided out patients with CSME in some of our analyses. In patients with retinopathy, we found
greater mean aqueous VEGF levels at progressively more severe levels of retinopathy in
accordance with other investigators27. Patients with CSME had the highest mean aqueous
VEGF levels, but these patients also all had severe NPDR or worse retinopathy. There were
too few events in which a change in CSF >11% from baseline occurred in this pilot study to
distinguish the influence of CSME or severity of retinopathy on the positive association with
mean aqueous VEGF or other factors.
We chose to measure CSF at one month since previous investigators found CSF following
cataract surgery to be greater at one month than at later time points7, but we also evaluated
those patients who were available for examination at 6 months. In a study from the Diabetic
Retinopathy Clinical Research Network, baseline or preoperative CSF values were found to
be important when analyzing postoperative values, specifically that a change in CSF of >11%
of the preoperative measurement was clinically significant and outside the error of
measurement present when using the Stratus OCT-325. This study also found that there was
better reproducibility in CSF than in foveal center point thickness measurements. In our study,
no growth factor measurement (serum VEGF, aqueous VEGF, or IGF-1) was strongly
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correlated with mean postoperative CSF at 1 month. However, even though only 6 patients had
a > 11% change from preoperative CSF at one month, aqueous VEGF was strongly associated
with a change in CSF >11% from the preoperative value at one month.
A previous study found no correlation in aqueous VEGF and CSF at the time of cataract surgery
in 17 patients with diabetes16. This study also found no correlation in CSF and aqueous VEGF,
both measured postoperatively, in 8 patients who had had an intravitreous injection of anti-
VEGF antibody, bevacizumab, 2 months prior to cataract surgery to treat CSME. In these
patients, aqueous VEGF was lower than in the 9 who had not had previous treatment with
intravitreous bevacizumab. The study differed from ours in that we determined associations
between preoperative aqueous VEGF levels and postoperative CSF at one and 6 months and
analyzed clinically meaningful measurements of > 11% change in CSF25. Few patients in our
study had increases in CSF that were >11% of preoperative values. This finding may be because
patients in our study had good glycemic control, and most had no or mild NPDR. Few had
CSME and of those who did, all had had preoperative laser treatment. Also, no patients
developed new onset CSME during the follow up period, and all cataract surgery was
uncomplicated.
High inter-patient variability in growth factor measurements has been reported in other
studies28,29,27,15. To minimize variability in growth factor measurements, we strove to keep
the time between collection of the sample and processing and storage at −80°C to within 2
hours of surgery. The mean serum VEGF in our study (283 pg/mL) was similar to studies in
the oncology (mean values ranging from 240 to 327 pg/mL) and ophthalmology literature
(mean 305 pg/mL). There is debate about whether serum or plasma samples should be obtained
to measure circulating VEGF levels. Many studies in the oncology literature report serum
VEGF values, because obtaining VEGF from the serum, rather than the plasma, includes that
bound to platelets, whereas platelet-bound VEGF is underrepresented in plasma samples30,
31,32. Several of these studies concluded that serum provided more useful data after direct
comparison with plasma measurements32,33, whereas others disagreed and favored plasma
measurements34. In addition, in the ophthalmology literature, there is disagreement, but several
studies35,36 reported serum measurements of VEGF as valuable in the management of diabetic
retinopathy. Therefore, we chose to measure serum VEGF in order to capture both bound and
unbound VEGF. We used commercially available ELISA kits with standard curves to
determine VEGF and IGF-1 protein in serum or aqueous and these analyses were completed
by the same masked laboratory technician. In future studies, it may be helpful to measure both
plasma and serum levels. However, we found that aqueous VEGF measurements appeared to
be of greater benefit than serum VEGF or IGF-1 measurements in our analyses.
In summary, our study found that aqueous VEGF was positively correlated with a clinically
meaningful percent change in CSF (>11% from the preoperative measurement25) at one month
following cataract surgery in diabetic patients. Our study suggests that aqueous VEGF may
lend predictive value when determining postoperative macular thickening in diabetic patients
undergoing cataract surgery and may be a useful measure in future trials. Larger studies are
recommended, particularly to dissect the potential value of aqueous VEGF and severity in
retinopathy as predictors.
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